Oobli Becomes First Company to Receive FDA “No Questions” Letter for a Novel Sweet Protein Produced via Precision Fermentation

“No questions” letter from US Food and Drug Administration signals support for the safety of the Oubli Fruit Sweet Protein for use in food and beverages DAVIS, Calif., March 20, 2024 /PRNewswire/ — Oobli, the leading global sweet protein platform known for its healthy sugar alternatives,…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks